Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Top Cited Papers
- 26 October 2011
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (13), 1222-1228
- https://doi.org/10.1016/s1470-2045(11)70265-0
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphomaBlood, 2011
- Beyond chemotherapy: new agents for targeted treatment of lymphomaNature Reviews Clinical Oncology, 2010
- Histone deacetylase inhibitors in Hodgkin lymphomaInvestigational New Drugs, 2010
- The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanismBritish Journal of Haematology, 2010
- Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemiaBritish Journal of Haematology, 2009
- Histone deacetylase inhibitors: Potential in cancer therapyJournal of Cellular Biochemistry, 2009
- Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell linesBlood, 2008
- Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2008
- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivoMolecular Cancer Therapeutics, 2008
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989